Search Result

Results for "

factor Xa inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Factor Xa (46) Autophagy (2) Drug Metabolite (3) Factor VIIa (1) Isotope-Labeled Compounds (2) Proteasome (2) SARS-CoV (1) Ser/Thr Protease (2) Thrombin (15)
By Research Areas:	Cancer (13) Cardiovascular Disease (45) Infection (1) Inflammation/Immunology (3) Metabolic Disease (2) Neurological Disease (1)
Oligonucleotides:	Aptamers (2)

Inhibitors & Agonists

Biochemical Assay Reagents

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: Factor Xa

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-76971

Dechloro Rivaroxaban	Factor Xa	Cardiovascular Disease
Dechloro Rivaroxaban is a highly selective, orally active inhibitor of Factor Xa. Dechloro Rivaroxaban inhibits human free FXa with a K_i of 0.4 nM. Dechloro Rivaroxaban inhibits prothrombinase activity and fibrin-associated FXa activity with IC₅₀s of 2.1 nM and 92 nM, respectively .

HY-B0597

Fondaparinux sodium 3 Publications Verification Fondaparin sodium; SR-90107A	Factor Xa	Cardiovascular Disease Cancer
Fondaparinux sodium is an antithrombin-dependent factor Xa inhibitor.

HY-10756

BMS-740808	Factor Xa	Cardiovascular Disease
BMS-740808 is a potent, selective and orally active factor Xa inhibitor with a K_i of 30 pM. BMS-740808 shows >1000-fold for factor Xa than other proteases .

HY-W854549

Heparin pentasaccharide Fondaparinux free acid	Factor Xa	Cardiovascular Disease
Heparin pentasaccharide (Fondaparinux) is a chemically synthesized selective factor Xa inhibitor with anticoagulant activity. Heparin pentasaccharide can be utilized in researches related to venous thromboembolic events .

HY-10777

EMD 495235	Factor Xa	Cardiovascular Disease
EMD 495235 is a potent and orally active *coagulation factor* Xa** inhibitor with an IC₅₀ of 5.5 nM and a K_i of 6.8 nM. EMD 495235 shows anticoagulant activities .

HY-12605

SAR107375	Thrombin	Metabolic Disease
SAR107375 is a potent and orally active dual thrombin and factor Xa inhibitor, with K_i values of 1 nM and 8 nM for factor Xa and thrombin, respectively .

HY-10724

Fidexaban	Factor Xa	Cardiovascular Disease
Fidexaban is a Factor Xa inhibitor and can be used in research of cardiovascular disease .

HY-11091

Razaxaban hydrochloride BMS 561389 hydrochloride; DPC 906 hydrochloride	Factor Xa Thrombin	Cardiovascular Disease
Razaxaban hydrochloride (BMS 561389 hydrochloride) is a highly potent, selective and orally active factor Xa inhibitor with a K_i of 0.19 nM. Razaxaban hydrochloride exhibits excellent selectivity (>5000-fold) for factor Xa over other related serine proteases. Razaxaban hydrochloride is also a potent thrombin inhibitor with a K_i of 540 nM. Razaxaban hydrochloride has strongly antithrombotic activity .

HY-11090A

DPC423	Factor Xa	Cardiovascular Disease
DPC423 is a highly potent, selective, and orally active factor Xa inhibitor with a K_i of 0.15 nM .

HY-B0597R

Fondaparinux sodium (Standard) Fondaparin sodium (Standard); SR-90107A (Standard)	Factor Xa	Cardiovascular Disease Cancer
Fondaparinux (sodium) (Standard) is the analytical standard of Fondaparinux (sodium). This product is intended for research and analytical applications. Fondaparinux sodium is an antithrombin-dependent factor Xa inhibitor.

HY-10268S

Betrixaban-d6	Factor Xa	Cardiovascular Disease
Betrixaban-d₆ is a deuterium labeled Betrixaban. Betrixaban is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor[1].

HY-153817

FXIa-IN-13	Factor Xa	Cardiovascular Disease
FXIa-IN-13 (example 1) is an Factor Xa inhibitor with antithrombotic activity. FXIa-IN-13 inhibits arteriovenous thrombosis in vivo and in vitro .

HY-129973

4-Chlorophenylurea NSC-12971; 4-Chlorophenylurea	Others	Others
4-Chlorophenylurea is metabolite of diflubenzuron (HY-B1973). 4-Chlorophenylurea can be used to form factor Xa inhibitors .

HY-19442

Idrabiotaparinux	Thrombin	Cardiovascular Disease
Idrabiotaparinux, a derivative of Idraparinux (HY-19691), is a novel synthetic anticoagulant that links Idraparinux, a specific, indirect factor Xa inhibitor, to biotin .

HY-17567A

Heparin sodium salt Maximum Cited Publications 38 Publications Verification Sodium heparin; Sodium heparinate	Thrombin Factor Xa Autophagy	Cardiovascular Disease Cancer
Heparin sodium salt (Sodium heparin) is an anticoagulant which binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes *thrombin factor* IIa** and factor Xa. Heparin sodium salt significantly inhibits exosome-cell interactions.

HY-118803

AS1468240	Factor Xa	Others
AS1468240 is an orally active inhibitor for *anticoagulant factor* Xa (fXa)*, that inhibits* human fXa with IC₅₀ of 8.7 nM. AS1468240 prolongs the coagulation time in mice .

HY-19373

RWJ-445167 3DP-10017	Thrombin Factor Xa	Cardiovascular Disease
RWJ-445167 (3DP-10017) is a dual inhibitor of thrombin and factor Xa with K_i of 4.0 nM and 230 nM, respectively, exhibiting potent antithrombotic activity.

HY-10268

Betrixaban 4 Publications Verification PRT054021	Factor Xa	Cardiovascular Disease
Betrixaban (PRT054021) is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC₅₀ of 1.5 nM. Betrixaban shows antithrombotic effect .

HY-10268B

Betrixaban hydrochloride PRT054021 hydrochloride	Factor Xa	Cardiovascular Disease
Betrixaban (PRT054021) hydrochloride is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC₅₀ of 1.5 nM. Betrixaban hydrochloride shows antithrombotic effect .

HY-10268A

Betrixaban maleate PRT054021 maleate	Factor Xa	Cardiovascular Disease
Betrixaban (PRT054021) maleate is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC₅₀ of 1.5 nM. Betrixaban maleate shows antithrombotic effect .

HY-10725

Tanogitran	Factor Xa	Cardiovascular Disease
Tanogitran is a dual inhibitor targeting Factor Xa and thrombin (thrombin), with K_i values of 26 and 2.7 nM, respectively. Tanogitran exhibits anticoagulant activity and can be used for research in thrombotic diseases .

HY-50903

Rivaroxaban 10+ Cited Publications BAY 59-7939	Factor Xa	Cardiovascular Disease Cancer
Rivaroxaban (BAY 59-7939) is a highly potent, selective and direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC₅₀ 0.7 nM; K_i 0.4 nM) .

HY-100655

O-Desmethyl apixaban	Drug Metabolite	Cardiovascular Disease
O-Desmethyl apixaban is a metabolite of Apixaban (BMS-562247-01) . Apixaban is a highly selective, reversible inhibitor of Factor Xa with K_i of 0.08 nM and 0.17 nM in human and rabbit, respectively .

HY-119124

Edoxaban M4 D21-2393	Drug Metabolite	Metabolic Disease
Edoxaban M4, an active metabolite of Edoxaban, shows reproducible, but concentration-dependent matrix effects. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor .

HY-153480

ARC19499 BAX499	Factor Xa	Others
ARC19499 is an aptamer that inhibits tissue factor pathway inhibitor (TFPI) , thereby enabling clot initiation and propagation via the extrinsic pathway. The core aptamer binds tightly and specifically to TFPI. ARC19499 blocks TFPI inhibition of both factor Xa and the TF/factor VIIa complex. ARC19499 corrects thrombin generation in hemophilia A and B plasma and restores clotting in FVIII-neutralized whole blood.

HY-153480A

ARC19499 sodium BAX499 sodium	Factor Xa Factor VIIa	Others
ARC19499 sodium is an aptamer that inhibits tissue factor pathway inhibitor (TFPI) , thereby enabling clot initiation and propagation via the extrinsic pathway. The core aptamer binds tightly and specifically to TFPI. ARC19499 sodium blocks TFPI inhibition of both factor Xa and the TF/factor VIIa complex. ARC19499 sodium corrects thrombin generation in hemophilia A and B plasma and restores clotting in FVIII-neutralized whole blood.

HY-17567AR

Heparin sodium salt (Standard) Sodium heparin (Standard); Sodium heparinate (Standard)	Factor Xa Autophagy Thrombin	Cardiovascular Disease Cancer
Heparin (sodium salt) (Standard) is the analytical standard of Heparin (sodium salt). This product is intended for research and analytical applications. Heparin sodium salt (Sodium heparin) is an anticoagulant which binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes *thrombin factor* IIa** and factor Xa. Heparin sodium salt significantly inhibits exosome-cell interactions.

HY-125528

Ro 09-1679	Thrombin	Cardiovascular Disease
Ro 09-1679 is a thrombin inhibitor, with an IC₅₀ of 33.6 μM. Ro 09-1679 inhibits the enzyme activities, with IC₅₀ values of 3.3, 0.04 and 0.0346 μM for factor Xa, trypsin and papain, respectively .

HY-50667S

Apixaban-13C,d3 BMS-562247-01-¹³C,d₃	Factor Xa	Cardiovascular Disease
Apixaban- ¹³C,d₃ is a deuterium and ¹³C labeled Apixaban. Apixaban is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively[1].

HY-W087937

Benzamidine hydrochloride hydrate 2 Publications Verification Benzenecarboximidamide hydrochloride hydrate	Ser/Thr Protease	Cancer
Benzamidine (Benzenecarboximidamide) hydrochloride hydrate is a reversible competitive trypsin-like serine proteases inhibitor with K_is of 20, 21, 97, 110, 320 and 750 μM against Tryptase, Trypsin, uPA, Factor Xa, Thrombin and tPA, respectively .

HY-50667

Apixaban 5+ Cited Publications BMS-562247-01	Factor Xa	Cardiovascular Disease Cancer
Apixaban (BMS-562247-01) is a highly selective, reversible and orally active inhibitor of Factor Xa with K_i of 0.08 nM and 0.17 nM in human and rabbit, respectively . Apixaban is in development for the prevention and treatment of various thromboembolic diseases .

HY-76948

5-R-Rivaroxaban	Factor Xa	Cardiovascular Disease
5-R-Rivaroxaban is (R)-enantiomer of Rivaroxaban. Rivaroxaban (BAY 59-7939) is a highly potent and selective, direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC₅₀ 0.7 nM; K_i 0.4 nM).

HY-18660B

Ciraparantag acetate PER977 acetate	Factor Xa	Cardiovascular Disease
Ciraparantag (PER977) acetate is a thrombin and factor Xa inhibitor. Ciraparantag acetate is a broad-spectrum reversal agent for anticoagulants, including low molecular weight heparins, unfractionated heparins, and some direct oral anticoagulants, but not VKAs .

HY-125505

BI-11634	Factor Xa	Cardiovascular Disease
BI-11634 is a factor Xa inhibitor. BI-11634 is metabolized by CYP3A4 to form one major metabolite and this reaction is inhibited by Quinidine (HY-B1751H) with a K_i of 7 µM .

HY-50903S

Rivaroxaban-d4 1 Publications Verification BAY 59-7939-d₄	Factor Xa	Cardiovascular Disease
Rivaroxaban-d₄ is a deuterium labeled Rivaroxaban. Rivaroxaban is a highly potent，selective and direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC50 0.7 nM; Ki 0.4 nM)[1][2].

HY-122592

Zifaxaban	Factor Xa	Cardiovascular Disease
Zifaxaban is an orally active, competitively and selective Factor Xa (FXa) inhibitor with an IC₅₀ of 11.1 nM for human FXa. Zifaxaban shows >10000-fold greater selectivity than other serine proteases. Zifaxaban can be used for the arterial and venous thrombosis research .

HY-14853

Darexaban YM150	Factor Xa Ser/Thr Protease	Cardiovascular Disease
Darexaban (YM150) is a potent, selective and orally active factor Xa (FXa) inhibitor with an IC₅₀ of 54.6 nM. Darexaban shows high selectivity against other related serine proteases, such as trypsin, thrombin, and kallikrein. Darexaban has anticoagulant and antithrombotic effects .

HY-18660

Ciraparantag PER977	Factor Xa	Cardiovascular Disease
Ciraparantag is a thrombin and factor Xa inhibitor. Ciraparantag is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban .

HY-134686

Edoxaban impurity 4	Factor Xa Thrombin	Cardiovascular Disease
Edoxaban impurity 4 is an impurity of Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with K_is of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention .

HY-50903R

Rivaroxaban (Standard)	Factor Xa	Cardiovascular Disease Cancer
Rivaroxaban (Standard) is the analytical standard of Rivaroxaban. This product is intended for research and analytical applications. Rivaroxaban (BAY 59-7939) is a highly potent, selective and direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC₅₀ 0.7 nM; K_i 0.4 nM) .

HY-10722

DX-9065a	Factor Xa	Cardiovascular Disease
DX-9065a is a selective, nonpeptidic, and orally active factor Xa (FXa) inhibitor with a K_i of 41 nM for human FXa. DX-9065a has low activity against other serine proteases. DX-9065a has strong anticoagulant actions .

HY-50667R

Apixaban (Standard)	Factor Xa	Cardiovascular Disease Cancer
Apixaban (Standard) is the analytical standard of Apixaban. This product is intended for research and analytical applications. Apixaban (BMS-562247-01) is a highly selective, reversible and orally active inhibitor of Factor Xa with K_i of 0.08 nM and 0.17 nM in human and rabbit, respectively . Apixaban is in development for the prevention and treatment of various thromboembolic diseases .

HY-100655R

O-Desmethyl apixaban (Standard)	Drug Metabolite	Cardiovascular Disease
O-Desmethyl apixaban (Standard) is the analytical standard of O-Desmethyl apixaban. This product is intended for research and analytical applications. O-Desmethyl apixaban is a metabolite of Apixaban (BMS-562247-01) . Apixaban is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively .

HY-76948R

5-R-Rivaroxaban (Standard)	Factor Xa	Cardiovascular Disease
5-R-Rivaroxaban (Standard) is the analytical standard of 5-R-Rivaroxaban. This product is intended for research and analytical applications. 5-R-Rivaroxaban is (R)-enantiomer of Rivaroxaban. Rivaroxaban (BAY 59-7939) is a highly potent and selective, direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC50 0.7 nM; Ki 0.4 nM).

HY-10264

Edoxaban 5+ Cited Publications DU-176	Factor Xa Thrombin	Cardiovascular Disease Cancer
Edoxaban (DU-176b) is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with K_i values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban can be used in preventing thromboembolic disease research .

HY-10264B

Edoxaban tosylate monohydrate 5+ Cited Publications DU-176b monohydrate	Factor Xa Thrombin	Cardiovascular Disease Cancer
Edoxaban (DU-176b) monohydrate is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with K_is of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban monohydrate exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban monohydrate can be used for preventing thromboembolic disease research .

HY-10264A

Edoxaban tosylate 5+ Cited Publications DU-176b	Factor Xa Thrombin	Cardiovascular Disease Cancer
Edoxaban (DU-176b) tosylate is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with K_is of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban tosylate exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban tosylate can be used for preventing thromboembolic disease research .

HY-10264C

Edoxaban hydrochloride DU-176 hydrochloride	Factor Xa Thrombin	Cardiovascular Disease
Edoxaban (DU-176b) hydrochloride is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with K_i values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban hydrochloride exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban hydrochloride can be used for preventing thromboembolic disease research .

HY-50667S1

Apixaban-d3 BMS-562247-01-d₃	Isotope-Labeled Compounds	Others
Apixaban-d₃ (BMS-562247-01-d₃)is the deuterium labeledApixaban(HY-50667) . Apixaban (BMS-562247-01) is a highly selective, reversible and orally active inhibitor of Factor Xa with K_i of 0.08 nM and 0.17 nM in human and rabbit, respectively . Apixaban is in development for the prevention and treatment of various thromboembolic diseases .

HY-10264S

Edoxaban-d6 DU-176-d₆	Factor Xa Thrombin	Cardiovascular Disease
Edoxaban-d₆ is deuterium labeled Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention. Edoxaban is also a weak inhibitor of thrombin and factor IXaβ (FIXa), with Kis of 6.00 μM and 41.7 μM, respectively, exhibits >10000-fold selectivity for FXa. Edoxaban has antithrombotic properties and has potential for thromboembolic diseases treatment .

Cat. No.	Product Name	Type

HY-W087937

Benzamidine hydrochloride hydrate 2 Publications Verification Benzenecarboximidamide hydrochloride hydrate	Biochemical Assay Reagents
Benzamidine (Benzenecarboximidamide) hydrochloride hydrate is a reversible competitive trypsin-like serine proteases inhibitor with K_is of 20, 21, 97, 110, 320 and 750 μM against Tryptase, Trypsin, uPA, Factor Xa, Thrombin and tPA, respectively .

HY-W854549

Heparin pentasaccharide Fondaparinux free acid	Carbohydrates
Heparin pentasaccharide (Fondaparinux) is a chemically synthesized selective factor Xa inhibitor with anticoagulant activity. Heparin pentasaccharide can be utilized in researches related to venous thromboembolic events .

Cat. No.	Product Name	Chemical Structure

HY-10268S

Betrixaban-d6
Betrixaban-d₆ is a deuterium labeled Betrixaban. Betrixaban is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor[1].

HY-50667S

Apixaban-13C,d3
Apixaban- ¹³C,d₃ is a deuterium and ¹³C labeled Apixaban. Apixaban is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively[1].

HY-50903S

Rivaroxaban-d4 1 Publications Verification
Rivaroxaban-d₄ is a deuterium labeled Rivaroxaban. Rivaroxaban is a highly potent，selective and direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC50 0.7 nM; Ki 0.4 nM)[1][2].

HY-10264S

Edoxaban-d6

Edoxaban-d₆ is deuterium labeled Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention. Edoxaban is also a weak inhibitor of thrombin and factor IXaβ (FIXa), with Kis of 6.00 μM and 41.7 μM, respectively, exhibits >10000-fold selectivity for FXa. Edoxaban has antithrombotic properties and has potential for thromboembolic diseases treatment .

HY-50667S1

Apixaban-d3
Apixaban-d₃ (BMS-562247-01-d₃)is the deuterium labeledApixaban(HY-50667) . Apixaban (BMS-562247-01) is a highly selective, reversible and orally active inhibitor of Factor Xa with K_i of 0.08 nM and 0.17 nM in human and rabbit, respectively . Apixaban is in development for the prevention and treatment of various thromboembolic diseases .

HY-18660S

Ciraparantag-d8 (tetra(hydrochloride) diacetate)

Ciraparantag-d8 tetrahydrochloride diacetate (PER977-d8 tetrahydrochloride diacetate) is the deuterium labeled Ciraparantag (HY-18660). Ciraparantag is a thrombin and factor Xa inhibitor. Ciraparantag is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban .

Cat. No.	Product Name		Classification

HY-153480A

ARC19499 sodium BAX499 sodium		Aptamers
ARC19499 sodium is an aptamer that inhibits tissue factor pathway inhibitor (TFPI) , thereby enabling clot initiation and propagation via the extrinsic pathway. The core aptamer binds tightly and specifically to TFPI. ARC19499 sodium blocks TFPI inhibition of both factor Xa and the TF/factor VIIa complex. ARC19499 sodium corrects thrombin generation in hemophilia A and B plasma and restores clotting in FVIII-neutralized whole blood.

HY-153480

ARC19499 BAX499		Aptamers
ARC19499 is an aptamer that inhibits tissue factor pathway inhibitor (TFPI) , thereby enabling clot initiation and propagation via the extrinsic pathway. The core aptamer binds tightly and specifically to TFPI. ARC19499 blocks TFPI inhibition of both factor Xa and the TF/factor VIIa complex. ARC19499 corrects thrombin generation in hemophilia A and B plasma and restores clotting in FVIII-neutralized whole blood.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: